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The pathophysiological response to a severe burn injury involves a robust increase in
circulating inflammatory/endocrine factors and a hypermetabolic state, both of which
contribute to prolonged skeletal muscle atrophy. In order to characterize the role of
circulating factors in muscle atrophy following a burn injury, human skeletal muscle
satellite cells were grown in culture and differentiated to myoblasts/myotubes in media
containing serum from burn patients or healthy, age, and sex-matched controls. While
incubation in burn serum did not affect NFκB signaling, cells incubated in burn serum
displayed a transient increase in STAT3 phosphorlyation (Tyr705) after 48 h of treatment
with burn serum (≈ +70%; P < 0.01), with these levels returning to normal by
96 h. Muscle cells differentiated in burn serum displayed reduced myogenic fusion
signaling (phospho-STAT6 (Tyr641), ≈−75%; ADAM12, ≈-20%; both P < 0.01),
and reduced levels of myogenin (≈−75%; P < 0.05). Concomitantly, myotubes
differentiated in burn serum demonstrated impaired myogenesis (assessed by number of
nuclei/myotube). Incubation in burn serum for 96 h did not increase proteolytic signaling
(assessed via caspase-3 and ubiquitin levels), but reduced anabolic signaling [p-p70S6k
(Ser421/Thr424),−30%; p-rpS6 (Ser240/244),≈ −50%] and impaired protein synthesis
(−24%) (P < 0.05). This resulted in a loss of total protein content (−18%) and reduced
cell size (−33%) (P < 0.05). Overall, incubation of human muscle cells in serum from
burn patients results in impaired myogenesis and reduced myotube size, indicating that
circulating factors may play a significant role in muscle loss and impaired muscle recovery
following burn injury.
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Introduction
Severe burn injury affecting greater than 20% of the total body surface area (TBSA) causes a robust
inflammatory response and an increased metabolic demand which contribute to rapid skeletal
muscle catabolism and ultimately lead to long-term muscle wasting (reviewed in Wolfe, 1981;
Pereira et al., 2005; Porter et al., 2013). The progressive loss of muscle mass negatively impacts the
rate of recovery by delaying wound healing, increasing the risk of infection, prolonging mechanical
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ventilator requirements, and delaying mobilization (reviewed
in Chang et al., 1998). Loss of 25% of total body nitrogen
can be fatal, and without nutritional supplementation beyond
normal caloric requirements, this amount of protein loss can
be reached within 3–4 weeks after the burn injury (Pereira
et al., 2005). While a combination of nutritional supplementation
and administration of anabolic hormones may attenuate muscle
loss in burn patients, a greater understanding of the cellular
mechanisms regulating muscle catabolism in this population
could help lead to the development of more targeted, effective
therapies.
Depending on the severity of the burn, the hypermetabolic
state can last up to several years post-injury (Jeschke et al., 2007,
2011) and is a likely contributor to the difficulty of returning
muscle mass to pre-injury levels. The hypermetabolic state in
burn patients is characterized by increased body temperature,
resting energy expenditure, glycogenolysis, proteolysis, lipolysis,
and futile substrate cycling (Wilmore and Aulick, 1978; Herndon
and Tompkins, 2004), which can contribute to significant muscle
protein degradation. Simultaneously, these patients are under
the burden of a hyperinflammatory state, characterized by a
substantial rise in pro-inflammatory cytokines [e.g., interleukin
(IL)-6, tumor necrosis factor (TNF)-α], many of which have
negative effects on muscle regeneration/growth (Jeschke et al.,
2008; Merritt et al., 2012). It has been clear for some time
that burn injury exerts profound effects on skeletal muscle at
sites distant from the actual injury, indicating humoral factors
such as inflammatory cytokines and stress hormones are at least
partially responsible. Recently, our lab has shown significantly
elevated calcium-mediated proteolytic signaling and ubiquitin-
proteasome activity in skeletal muscle of human burn patients
distant from the burn (Merritt et al., 2012), indicating hyperactive
muscle catabolism. Concomitantly, these patients had robust
elevations in circulating cytokines (up to 70-fold greater than
control), as well as elevated inflammatorymuscle gene expression
(Merritt et al., 2012, 2013b), suggesting that systemic factors may
indeed play a key role in muscle wasting in burn patients.
Whole organism burn models make it difficult to discern
whether muscle protein loss is due primarily to intrinsic (e.g.,
hypermetabolism causing muscle proteolysis) or systemic (e.g.,
increases in circulating cytokines and/or endocrine factors)
effects of the burn injury. Therefore, the aim of this project was
to use an in vitro system to determine the effect of serum from
severely burned patients (≈30% TBSA burn) on the growth,
differentiation, and cellular signaling of skeletal muscle cells
obtained from healthy humans. We hypothesized that treatment
with burn serum would impair growth and differentiation of
human myotubes, and reduce rates of protein synthesis, which
would provide in vitro evidence to support the central hypothesis
that circulating factors exert profound effects on non-burned
skeletal muscle of burn patients.
Materials and Methods
Subjects
Six patients with 20–60% TBSA burns were recruited from the
regional burn center. Blood samples from these individuals were
obtained within 3–10 days following burn injury, and serum
was isolated by centrifugation. Serum from sex and age matched
healthy adults (n = 6) was obtained from the Core Muscle
Research Laboratory’s de-identified serum bank and used as
control for all experiments. The study was approved by the local
Institutional Review Board and patients gave written informed
consent prior to participation.
Cell Culture
Satellite cells isolated from the vastus lateralis of three healthy
males (≈30 year) were obtained from the Core Muscle Research
Laboratory’s de-identified cryostorage bank. Serum from the
six burn-injured patients was pooled and designated as “burn”
serum. Serum from healthy age and sex matched donors was
pooled and designated as “control” serum. Satellite cells were
grown to≈80% confluence, and then treated with differentiation
media (DMEM containing 100µL/mL streptomycin, 100U/mL
penicillin, and 5% human serum) with either 5% burn or control
serum in side-by-side parallel experiments. Differentiationmedia
was changed every 48 h, and cells were lysed at 48 and 96 h.
Protein synthesis rates were assessed at 96 h using the surface
sensing of translation (SUnSET) technique (Schmidt et al., 2009),
which involved a 30min puromycin pulse (1µM; Sigma-Aldrich,
St. Louis, MO) prior to lysing.
Immunocytochemistry
To examine the effects of burn serum onmyogenic differentiation
and myotube size, cells differentiated for 96 h were stained for
myosin heavy chain protein expression. After being fixed with
methanol for 20min and washed with PBS, cells were blocked
in 5% goat serum with 0.1% Triton X-100 for 20min. Cells
were incubated overnight at 4◦C with MF-20 primary antibody
(Developmental Studies Hybridoma Bank; 25µg/mL) in 5% goat
serum. After washing in PBS, cells were incubated in secondary
Ab (Alexa Fluor 488 goat-anti-mouse, Life Technologies, Grand
Island NY; 1:200) in 1% goat serum at room temperature for 1 h.
Cells were washed with PBS and coverslips were mounted with
ProLong Gold (Life Technologies) with DAPI (4′,6-diamidino-
2-phenylindole) for nuclei labeling. Using an Olympus BX51
fluorescent microscope with an Olympus MagnaFire SP camera
(S99810), images were captured at 10X and 4X magnifications
for analysis of myotube fusion and volume, respectively. Image
analysis of myotube fusion (i.e., the number of nuclei per
myotube) was performed using Image-Pro Plus 6.0 software.
The percentage of myotubes containing five or more nuclei
was used for analysis as a marker of myogenic fusion. Analysis
of myotube volume was performed according to previously
established protocols (Agley et al., 2012) using Adobe Photoshop
version CS6.
Immunoblotting
Cells were lysed in 150µL of ice cold RIPA buffer containing
protease and phosphatase inhibitors. Cell lysate was centrifuged
at 5000 g for 5min at 4◦C. The supernatant was assayed for
protein content using the bicinchonic acid technique with BSA
as a standard. Cell protein lysate (20µg) was resolved on 4–12%
SDS-PAGE gels and transferred to PVDF membranes. Analysis
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of inflammatory, fusion/differentiation, and anabolic/catabolic
signaling pathways was performed by standard immunoblotting.
Antibodies raised against phosphorylated (Ser536) and total
NFκB p65, phosphorylated (Ser421/Thr424) and total p70S6k,
phosphorylated (Ser240/244) and total rpS6, phosphorylated
(Tyr705 and Ser727) and total STAT3, phosphorylated (Tyr641)
and total STAT6, ADAM12, ubiquitin, caspase-3, and α-
tubulin were from Cell Signaling Technologies (Danvers,
MA), while antibodies for myogenin and MyoD were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and anti-
puromycin antibody was from Millipore (Billerica, MA).
Primary antibodies were diluted 1:1000 in PBST and 5% goat
serum (monoclonal antibodies) or 2% milk/2% BSA (polyclonal
antibodies). HRP-conjugated secondary antibody (Pierce
Thermoscientific, Rockford, IL) was used at 1:50,000 (w/v)
followed by chemiluminescent detection in a BioRad (Hercules,
CA) ChemiDoc imaging system with band densitometry
performed using BioRad Quantity One software (software
package 4.5.1). Equal loading was verified by Ponceau-S staining
of the PVDF membranes prior to immunoblotting. In addition,
α-tubulin served as a loading control within each time point (i.e.,
48 or 96 h). There were no statistically significant differences
in α-tubulin levels between control vs. burn-treated cells in
any of the control vs. burn comparisons at 48 or 96 h. While
not a primary comparison, we also found no statistically
significant differences in α-tubulin levels between 48 and 96 h;
however, the appearance of an increase (e.g., Figure 1) is not
unexpected. During myogenesis, microtubule accumulation and
reorganization occurs, which could lead to an accumulation of
α-tubulin from 48 to 96 h of differentiation. It is therefore not
surprising that others have noted an increased amount of total
tubulin content during myoblast differentiation (Gundersen
et al., 1989). Regardless, all of our comparisons between burn
and control occurred at single time points (48 or 96 h), not across
time.
Statistics
For each experiment, cells treated with burn serum were studied
in parallel with cells treated with healthy, control serum. All data
in each burn serum experiment were then normalized to control
serum conditions. Unpaired t-tests were used to determine
differences in myogenic fusion, myotube volume, and signaling
protein levels between cells treated with burn and control serum.
Significance was accepted at P < 0.05.
Results
Effects of Burn Serum on Inflammatory Signaling
Inflammatory cytokine signaling through the well-characterized
TNF-α/NFκB and IL-6/STAT3 pathways has been shown to
induce skeletal muscle atrophy in vivo (Coletti et al., 2005;
Haddad et al., 2005). We have previously shown that serum
from burned patients contained 5- and 70-fold higher levels
of TNF-α and IL-6 compared to control serum, respectively,
although heightened TNF- α/NFκB or IL-6/STAT3 signaling
were not evident in the muscles of these patients (Merritt
et al., 2012). Similarly, treatment of primary human muscle cells
with burn serum in the current study did not induce robust
TNF- α/NFκB signaling. Specifically, treatment with burn serum
did not increase the phosphorylation of NFκB p65 at Ser536
(which directs NFκB nuclear translocation and activation) at any
time when compared to control serum (Figure 1). There was a
significant increase in STAT3 phosphorlyation at Tyr705 after
48 h of treatment with burn serum (+71%; P < 0.01), but these
levels returned to normal by 96 h. Increased phosphorylation at
the site which directs STAT3 transcriptional activity (Ser727) was
not found (P = 0.09 at 48 h). By 96 h, there was a slight increase
in total STAT3 protein content (+15%; P < 0.001) in cells treated
with burn serum. These data indicate that serum obtained from
burn patients does not induce NFκB signaling inmuscle cells, and
induces a prolonged activation of IL-6/STAT3 signaling.
Effects of Burn Serum on Myogenic Signaling
The activation, proliferation, and differentiation of muscle
satellite cells are required for muscle regeneration from injury,
and fusion of differentiated/committed satellite cells (i.e., fusion-
competent myoblasts) with existing myofibers supports myofiber
FIGURE 1 | Effects of burn serum on inflammatory NFκB and STAT3 signaling. ∗Different from control at respective time point; P < 0.05. Dotted line represents
control values. Representative blots for α-tubulin demonstrate equal loading between burn and control lanes.
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hypertrophy. We found reduced levels of proteins that regulate
myogenic fusion (Figure 2A) and differentiation (Figure 2B)
in muscle cells differentiated in burn serum, confirming that
burn serum creates an anti-myogenic environment, which likely
contributes to impaired muscle regrowth following burn injury-
induced muscle atrophy. Levels of p-STAT6 (Tyr641), a marker
of IL-4 mediated myoblast fusion, were ≈75% lower at 48 and
96 h (P < 0.01 for both) in muscle cells incubated in burn
serum compared to control. Additionally, levels of ADAM12
(disintegrin and metalloproteinase domain-containing protein
12), a transmembrane metalloproteinase that is required for
myoblast fusion (Galliano et al., 2000), was 22% lower (P < 0.01)
after 96 h of differentiation in burn serum.
Regarding myogenic differentiation, myogenin, the
putative myogenic regulatory factor responsible for terminal
differentiation, increased as expected from 48 to 96 h of
differentiation in control, but was substantially suppressed in
response to burn serum at both 48 and 96 h compared to control
(57 and 74% lower, respectively; P < 0.05). MyoD, an early
marker of commitment to the myogenic lineage, appeared to be
expressed at extremely high levels with burn serum treatment
(10-fold higher at 48 h, and six-fold higher at 96 h, albeit
non-significant due to high variability). Together these findings
FIGURE 2 | Effects of burn serum on markers of myogenic fusion (A)
and myogenic differentiation (B). ∗Different from control at respective time
point; P < 0.05. Dotted line represents control values.
suggest burn serum suspended myoblasts in an early phase of
differentiation; thereby limiting terminal differentiation and
fusion.
Effects of Burn Serum on Protein Metabolism
Signaling
Skeletal muscle loss caused by burn injury is due to an increase
in muscle protein breakdown, a decrease in muscle protein
synthesis, or a combination of both of these factors. We therefore
examined both markers of protein breakdown and synthesis in
myotubes treated with burn and control serum (data shown in
Figure 3). Interestingly, caspase-3 levels were significantly lower
in muscle cells treated with burn serum for 96 h (−20%; P <
0.01), and total protein ubiquitination tended to be lower as
well (−12%; P = 0.06) when compared to control. Thus, burn
serum did not appear to up-regulate proteolysis in this in vitro
model. On the other hand, anabolic signaling was suppressed
in muscle cells treated with burn serum for 96 h, as evidenced
by significant decreases in p-p70S6k (Ser421/Thr424) (−30%)
and p-rpS6 (Ser240/244) (−46%) (both P < 0.05). In parallel
with these findings, protein synthesis rate, measured via the
SUnSET method, was suppressed 24% (P < 0.001) in muscle
cells treated with burn serum compared to control (Figure 3B).
These in vitro findings suggest serum from burn patients causes
negative protein balance by blunted anabolic signaling and
protein synthesis but not up-regulated proteolysis.
Effects of Burn Serum on Myoblast Fusion and
Myotube Size
In agreement with the signaling data, the addition of burn serum
to healthy muscle cells ultimately resulted in reduced myotube
formation and myotube size (representative images shown in
Figures 4A,B). Incubation in burn serum for 96 h did not result
in cell death (assessed by total nuclei/image; control: 248 ±
53 nuclei/image; burn: 237 ± 38 nuclei/image), but did reduce
the number of nuclei per myotube (55% fewer myotubes with
5+ nuclei; P < 0.05), indicating impaired fusion compared
to control (Figure 4C). Additionally, myotubes grown in burn
serum had significantly reduced total protein content (−18%,
P < 0.05; data not shown) and myotube size was 33% smaller
(P < 0.05) compared to control (Figure 4D).
Discussion
Although the effects of severe burn injury on skeletal muscle loss
are well-documented (Wolfe, 1981; Hart et al., 2000; Pereira et al.,
2005; Jeschke et al., 2008, 2011), the major mechanisms driving
net negative muscle protein balance in burn patients are largely
unknown. Changes in whole body metabolism as well as changes
in the systemic milieu (e.g., circulating cytokines, endocrine
factors) both likely contribute to muscle wasting. Here, using an
in vitro system, we show that serum obtained from burn patients
significantly reduces myoblast differentiation and fusion, and
myotube size in healthy primary human muscle cells. The effect
of burn serum on reducing myoblast differentiation/fusion seems
to be regulated via decreases in signaling pathways directing
fusion (e.g., p-STAT6 and ADAM12) as well as dysregulation
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FIGURE 3 | Effects of burn serum on anabolic/catabolic signaling (A) and protein synthesis measured via the SUnSET method (B). ∗Different from control
at respective time point; P < 0.05. Dotted line represents control values.
of myogenic regulatory factors (e.g., myogenin and MyoD).
Interestingly, the effect of burn serum on reducing myotube
size does not appear to be driven by an upregulation of
protein breakdown; rather, a decrease in anabolic signaling (e.g.,
p70S6k/rpS6) and cellular protein synthesis. Overall, these results
indicate that burn serum, on its own, can cause significant
decreases in muscle cell size via impaired fusion and suppression
of cellular protein synthesis.
Following a severe burn injury, the body presents a stress
response, releasing abundant amounts of pro-inflammatory
cytokines, and hormones (Jeschke et al., 2008). Marked increases
in circulating cytokines would be expected to affect skeletal
muscle in a negativemanner, as excess levels of pro-inflammatory
cytokines such as TNF-α and IL-6 can activate downstreamNFκB
and STAT3 signaling, respectively, ultimately leading to muscle
wasting and impaired muscle regeneration (Szalay et al., 1997;
Coletti et al., 2005; Haddad et al., 2005; Merritt et al., 2013a).
We (Merritt et al., 2012) and others (Jeschke et al., 2008) have
previously reported robust elevations of these cytokines (e.g.,
>100-fold elevations in IL-6) in serum obtained from burn
patients, although we have shown that, despite these elevations,
pro-inflammatory NFκB and STAT3 signaling in non-burned
skeletal muscle tissue is not elevated (Merritt et al., 2012). The
results of the present study corroborate with these findings, as
healthy muscle cells treated with burn serum in vitro did not
demonstrate an increase in NFκB signaling. While there was
a significant increase in p-STAT3 (Tyr705) in response to 48 h
burn serum treatment, this effect was transient, with levels of p-
STAT3 (Tyr705) returning to normal by 96 h. It is important to
note that phosphorylation of STAT3 at Tyr705 is required for
STAT3 dimerization, nuclear translocation, and DNA binding,
however, phosphorylation of STAT3 at Ser272 is required for
maximal transcriptional activity of STAT3 dimers in the nucleus
(Wen et al., 1995). Phosphorylation of STAT3 on Ser727 only
displayed a trend toward an increase following 48 h of burn
serum treatment (+17%, P = 0.09), and normal levels by
96 h. Taken together, the increase in p-STAT3 (Tyr705) at 48 h,
and the mild, non-significant increase in p-STAT3 (Ser727) at
96 h indicate that burn serum does not induce a prolonged
inflammatory response in muscle cells via STAT3. Rather, robust
activation of STAT3 (and perhaps even NFκB) signaling are likely
to occur at earlier time points following burn serum treatment
in vitro, as well as during early time points following acute burn
injury in vivo.
Recovery from a burn injury is likely to involve the activation
and differentiation of skeletal muscle satellite cells, as these
cells would be necessary for muscle tissue repair if any damage
has occurred during the initial injury. Additionally, myonuclear
addition via fusion of satellite cells into existing myofibers may
help facilitate protein synthesis within the myofiber during long-
term recovery from the injury (Adams and Bamman, 2012). Wu
et al. (2013) have recently shown that satellite cells are activated
in rat muscle following burn injury in vivo, and that burn serum
from rats can activate myoblasts in vitro, although they did not
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FIGURE 4 | Effects of burn serum on myogenic fusion (C) and myotube size (D). (A,B) are representative immunocytochemical images of myotubes
differentiated in control (A) or burn (B) serum. ∗Different from control at respective time point; P < 0.05.
assess the effects of burn serum on the differentiation of these
cells. Here, we show that treatment with burn serum reduces the
myogenic fusion and differentiation of healthy, human muscle
cells in vitro. Myoblast fusion occurs in two phases: in the first
phase, myoblasts fuse together to form a nascent myotube, and in
the second phase, myoblasts fuse with nascent myotubes to form
mature myotubes (Horsley and Pavlath, 2004). Thus, we chose to
measure signaling proteins that regulate both the first (ADAM12)
and second (IL-4/STAT6) phases of myoblast fusion. Burn serum
treatment reduced protein levels of ADAM12, a transmembrane
metalloprotease that is required for phase 1 myoblast fusion
(Galliano et al., 2000), and the phosphorylation state of STAT6
(Tyr641), which is activated via IL-4 and directs phase 2 fusion
(Horsley et al., 2003). These results show that burn serum
exerts profound effects on reducing both phase 1 and phase 2
fusion in myogenic cells. Relevant to these data, muscle cells
differentiated in burn serum had significantly reduced expression
of myogenin (less than half that of control), and robustly
elevated levels of MyoD (6-10-fold higher) compared to control,
indicating aberrant regulation of the myogenic program caused
by burn serum. Altogether, dysregulation of these pathways
regulating terminal differentiation and myogenic fusion resulted
in a quantifiable reduction in the number of myonuclei per
myotube. Clearly, burn serum can reduce the differentiation and
fusion of primary human myoblasts, which likely translates into
impaired muscle recovery following a burn injury.
Themost important determinant of howmuch skeletal muscle
is lost following a burn injury is the net protein balance of
the patient. Hart et al. (2000) have shown that a negative net
protein balance persists up to 9 months following severe burn
injury. This indicates that, in burn patients, muscle protein
breakdown is increased, and/or protein synthesis is decreased.
Muscle protein breakdown is due to hypermetabolism, with
preferential breakdown of skeletal muscle as a primary source
of nitrogen and energy (Pereira et al., 2005). In accordance
with this, we have previously shown an increased expression of
the muscle-specific E3 ubiquitin ligases, atrogin-1 and MuRF1,
as well as markers of proteolytic signaling (e.g., ubiquitin-
proteasome activity and calcium-mediated proteolysis) in human
whole muscle tissue following burn injury (Merritt et al., 2012,
2013b). The results of the current study do not agree with our
previous findings, as levels of caspase-3 were actually lower in
muscle cells treated with burn serum, and total ubiquitination
tended to be lower (albeit non-significant) when compared to
control. Levels of caspase-3 could be indicative of muscle protein
breakdown, as caspase-3 cleaves myofibrils into monomeric actin
and myosin prior to degradation via the ubiquitin-proteasome
system (Du et al., 2004). Interestingly, however, caspase-3 is also
required for muscle differentiation, and inhibition of caspase-3
severely reduces myogenesis (Fernando et al., 2002). In the
current study, levels of caspase-3 increased during the time
course of differentiation, with the control serum-treated group
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increasing caspase-3 levels≈50% from 48 to 96 h, while the burn-
treated group only increased caspase-3 levels ≈20% from 48 to
96 h (data not shown). Thus, based on these observations, the
reduced caspase-3 content in the burn-serum treated group may
not be a reliable marker of overall protein breakdown; rather, it
may just be a consequence of impaired myogenesis in this group.
Nevertheless, there was not a significant increase in total protein
ubiquitination following treatment with burn serum, suggesting
burn serum may not play a major role in the muscle proteolysis
that has been observed in whole tissue studies.
While we did not find any increases in markers of protein
breakdown, the significant reduction in myotube size following
treatment with burn serum was linked to an attenuation of
protein synthesis. Indeed, we found that protein synthesis was
reduced by ≈25% in myotubes grown in burn serum vs. control.
In order to elucidate the mechanisms responsible for repressed
anabolism in burn serum treatment, we examined the putative
mammalian target of rapamycin (mTOR) pathway, which is
a major pathway involved in muscle mass regulation. mTOR
is a protein kinase that integrates a variety of intracellular
signals, including those arising due to nutrient availability (or
lack thereof), growth factor stimulation, and stress responses
(Frost and Lang, 2011; Laplante and Sabatini, 2012). As part
of the active mTORC1 complex, mTOR phosphorylates several
downstream targets, including the 70-kilodalton S6 protein
kinase (p70S6k), which, in turn, phosphorylates ribosomal
protein S6 (rpS6). Treatment of healthy muscle cells with
burn serum effectively reduced phosphorylation of the auto-
inhibitory domain (Ser421/Thr424) of p70S6k by ≈30%, and in
turn, reduced levels of p-rpS6 (Ser240/244) by ≈30%. Reduced
p70S6k/rpS6 signaling is likely a major factor contributing to
attenuated protein synthesis in myotubes grown in burn serum;
however, the mechanisms regulating this are not known.
Although we have shown definitive evidence that serum
obtained from burn patients is a sufficient stimulus to reduce
myogenesis and blunt protein synthesis, it remains unknown
exactly which factors in the serum contribute to these effects.
Numerous immunologic and endocrine factors have been found
to be drastically different in serum obtained from burn patients
when compared to control serum, such as: complement, C-
reactive protein, interferon γ, TNF-α, interleukins-1β, 2, 4, 5, 6, 7,
8, 10, 12, 13, and 17, catecholamines, insulin-like growth factor-
1 (IGF-1), IGF-1 binding protein-3 (IGFBP-3), growth hormone
(GH), testosterone, thyroxine (T4), and cortisol (Crum et al.,
1990; Jeffries and Vance, 1992; Jeschke et al., 2008; Merritt et al.,
2012). Our data suggest that, despite large increases in circulating
TNF-α and IL-6, the rise in these pro-inflammatory cytokines is
not enough to activate downstream NFκB and STAT3 signaling
in skeletal muscle for a prolonged period of time. However, it is
important to note that the burn serum in this study comprised
only 5% of the total media in these experiments; thus, the muscle
cells may have had a significant sustained inflammatory signaling
response if they were exposed to a higher concentration of
serum. Knowledge from previous studies (Moller et al., 1991;
Jeschke et al., 2008) showing that IGF-1 and IGFBP-3 are
reduced in the serum of burn patients makes it interesting to
speculate that the reduction in p70S6k signaling was due to
reduced availability of IGF-1 to bind to its cognate receptor and
activate the putative IGF-1/Akt/mTOR/p70S6k pathway. Rescue
of this signaling pathway via administration of IGF-1 or IGFBP-
3 has been shown to improve muscle protein synthesis in burn
patients (Herndon et al., 1999). Follow-up in vitro experiments
should examine other signaling pathways that are known to be
influenced by levels of circulating cytokines/hormones that are
dysregulated in burn serum.
In conclusion, exposure of healthy muscle cells to media
containing burn serum results in impaired myogenesis and
a reduction in myotube size, implicating humoral factors as
a contributor to burn-induced long-term muscle loss. While
the reduction in myotube size appears to be via blunted
p70S6k signaling and reduced protein synthesis, it is not
clear exactly which factors in burn serum are contributing to
this. Future studies should consider proteomic techniques to
fully characterize the components altered in burn serum that
may regulate burn-induced atrophy and/or impaired muscle
regrowth. A greater understanding of which specific factors in
burn serum contribute to reduced myogenesis and muscle cell
size will be beneficial for developing more targeted therapies to
counteract burn-induced skeletal muscle loss.
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